Biogen and City Therapeutics Partnership to Develop New RNAi Therapies
Wednesday, May 28, 2025
Biogen and City Therapeutics have announced a strategic collaboration to develop selected novel RNAi therapies.
The partnership will see City Therapeutics apply its advanced RNAi engineering technology to create an RNAi trigger molecule, which will be combined with Biogen’s proprietary drug delivery system.
The initial focus will be on a single target involved in key central nervous system disorders, using enhanced tissue delivery technologies aimed at enabling systemic administration of treatments.
Biogen will lead the investigational new drug (IND) enabling studies, global clinical development, regulatory filings, and all commercial activities.
This collaboration reflects Biogen’s approach to complement its internal research capabilities with external investments in innovative science. By incorporating RNAi technology, Biogen intends to expand its range of therapeutic methods to improve targeting of disease mechanisms.
City Therapeutics views this partnership as a significant step towards broadening the therapeutic applications of RNAi.
By combining its RNAi platform with Biogen’s expertise in drug development and global reach, the collaboration aims to accelerate the development of treatments for serious medical conditions with unmet needs.
Source: globenewswire.com
